Skip to main content

Table 1 Patients’ characteristics

From: Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera

  ET PV Total
N, (%) 305 (64) 172 (36) 477
Sex (M/F), n (%) 112/193 (37/63) 91/81 (53/47) 203/274 (43/57)
Age, years,
median (5th–95th percentiles)
58.0 (27.7–83.0) 58.3 (35.5–82.0) 58.0 (28.3–82.7)
Mutational status, n (%)
 Triple negatives 57 (18) 9 (5) 66 (14)
 CALR 44 (14) 0 (0) 44 (9)
 MPLW515L/K 14 (5) 0 (0) 14 (3)
 JAK2V617F hetero 176 (58) 95 (55) 271 (57)
 JAK2V617F homo 14 (5) 64 (37) 78 (16)
 JAK2 exon 12 mutation 0 (0) 4 (2) 4 (1)
Hs-CRP, mg/L,
median (5th–95th percentiles)
0.83 (0.03–7.96) 0.87 (0.03–6.43) 0.83 (0.03–7.53)
PTX3, ng/mL,
median (5th–95th percentiles)
4.55 (0.58–14.95) 5.88 (0.42–22.96) 4.83 (0.54–18.48)
  1. ET essential thrombocythemia, PV polycythemia vera, hetero heterozygous, homo homozygous